HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and...

Full description

Saved in:
Bibliographic Details
Main Authors RAGHUNADHA REDDY BURRI, SRIDHARAN RAJAGOPAL, SUBRAMANIAM KANAGARAJ, MANISH KUMAR THAKUR, SAYANTANI SARKAR, SHIVANI GARAPATY, SWAPAN KUMAR SAMANTA, DHANALAKSHMI SIVANANDHAN, TAMIZHARASAN NATARAJAN, ZAINUDDIN MOHD, NAGENDRA NAGARAJU, INDU N SWAMY, SARAVANAN VADIVELU, HARIPRAKASH
Format Patent
LanguageEnglish
Published 21.12.2022
Online AccessGet full text

Cover

More Information
Summary:The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
Bibliography:Application Number: ZA20200003778